Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015
Research

Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010

Sarah E. SmithComments to Author , Julia Ershova, Natalia Vlasova, Elena Nikishova, Irina Tarasova, Platon Eliseev, Andrey Maryandyshev, Igor G. Shemyakin, Ekaterina V. Kurbatova, and J. Peter Cegielski
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.E. Smith, J. Ershova, E. Kurbatova, J.P. Cegielski); Arkhangelsk Regional Tuberculosis Dispensary, Arkhangelsk, Russia (N. Vlasova, E. Nikishova, I. Tarasova, P. Eliseev, A.O. Maryandyshev); Northern State Medical University, Arkhangelsk (A.O. Maryandyshev); State Research Center for Applied Microbiology and Biotechnology, Obolensk, Russia (I.G. Shemyakin)

Main Article

Table 2

Risk factors for acquired resistance to CAP while receiving treatment for MDR TB, 158 patients, Arkhangelsk Oblast, Russia, 2005–2010*

Variable† Total Acquired capreomycin resistance, no. (%)
 p value‡
Yes No
Received ≥3 effective drugs
Yes 126 0 126 (100) 0.008
No 32 3 (9.4) 29 (90.6)
Ever received effective FQ treatment§
Yes 148 1 (0.7) 147 (99.3) 0.009
No 9 2 (22.2) 7 (77.8)
Ever received effective PAS treatment§
Yes 110 0 (0) 110 (100) 0.02
No 46 3 (6.5) 43 (93.5)
Previous treatment with FQ
Yes 28 2 (7.1) 26 (92.9) 0.08
No 130 1 (0.8) 129 (99.2)
Previous PAS treatment¶
Yes 23 2 (8.7) 21 (91.3) 0.08
No 112 1 (0.9) 111 (99.1)
First time patient treated for MDR TB
Yes 134 1 (0.7) 133 (99.3) 0.06
No 24 2 (8.3) 22 (91.7)
Baseline ofloxacin DST result
Resistant 9 2 (22.2) 7 (77.8) 0.008
Susceptible 149 1 (0.7) 148 (99.3)
Baseline PAS DST result
Resistant 47 3 (6.4) 44 (93.6) 0.03
Susceptible 111 0 (0) 111 (100)
Received OFX during episode
Yes 135 0 (0) 135 (100) 0.003
No 23 3 (13) 20 (87)
Received MOX during episode
Yes 31 3 (9.7) 28 (90.3) 0.007
No 127 0 (0) 127 (100)

*CAP, capreomycin; DST, drug-susceptibility test; FQ, fluoroquinolone; MDR TB, multidrug-resistant tuberculosis; MOX, moxifloxacin; OFX, ofloxacin; PAS, para-aminosalicylic acid.
†Certain variables were tested for association but omitted from table because results were not statistically significant at α = 0.1.
‡Fisher exact test.
§Patient(s) who did not receive treatment with the respective drug during the current episode of MDR TB were not included in the analysis.
¶For 23 patients, history of treatment with PAS was unknown.

Main Article

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external